Half-year report · HY

Period2026-01-01 → 2026-06-30
Filed2026-08-13
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥274m2026-01-01 → 2026-06-30StandaloneNet sales
Revenue¥593m2025-01-01 → 2025-12-31StandaloneNet sales (5-year summary)
Revenue¥252m2025-01-01 → 2025-06-30StandaloneNet sales
Operating income−¥480m2026-01-01 → 2026-06-30StandaloneOperating income
Operating income−¥537m2025-01-01 → 2025-06-30StandaloneOperating income
Ordinary income−¥482m2026-01-01 → 2026-06-30StandaloneOrdinary income
Ordinary income−¥989m2025-01-01 → 2025-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥539m2025-01-01 → 2025-06-30StandaloneOrdinary income
Profit before tax−¥482m2026-01-01 → 2026-06-30StandaloneIncome before income taxes
Profit before tax−¥539m2025-01-01 → 2025-06-30StandaloneIncome before income taxes
Net income−¥483m2026-01-01 → 2026-06-30StandaloneProfit loss
Net income−¥983m2025-01-01 → 2025-12-31StandaloneNet income loss (5-year summary)
Net income−¥540m2025-01-01 → 2025-06-30StandaloneProfit loss
Total assets¥1.9bnat 2026-06-30StandaloneAssets
Total assets¥1.7bnat 2025-12-31StandaloneAssets
Total assets¥2.0bnat 2025-06-30StandaloneTotal assets (5-year summary)
Total liabilities¥341mat 2026-06-30StandaloneLiabilities
Total liabilities¥605mat 2025-12-31StandaloneLiabilities
Net assets / equity¥1.6bnat 2026-06-30StandaloneNet assets
Net assets / equity¥1.1bnat 2025-12-31StandaloneNet assets
Net assets / equity¥1.5bnat 2025-06-30StandaloneNet assets (5-year summary)
Cash and deposits¥1.4bnat 2026-06-30StandaloneCash and deposits
Cash and deposits¥1.2bnat 2025-12-31StandaloneCash and deposits
Cash & equivalents¥1.4bnat 2026-06-30StandaloneCash and cash equivalents
Cash & equivalents¥1.2bnat 2025-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.5bnat 2025-06-30StandaloneCash and cash equivalents
Cash & equivalents¥2.1bnat 2024-12-31vStandaloneCash and cash equivalents
Operating cash flow−¥539m2026-01-01 → 2026-06-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥936m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥673m2025-01-01 → 2025-06-30StandaloneNet cash provided by used in operating activities
Investing cash flow−¥4m2026-01-01 → 2026-06-30StandaloneNet cash provided by used in investment activities
Investing cash flow−¥55m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥710m2026-01-01 → 2026-06-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥133m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥85m2025-01-01 → 2025-06-30StandaloneNet cash provided by used in financing activities
EPS (basic)¥-6.622026-01-01 → 2026-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-14.472025-01-01 → 2025-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-7.972025-01-01 → 2025-06-30StandaloneBasic earnings loss per share (5-year summary)
Equity ratio81.9%at 2026-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio64.1%at 2025-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio76.9%at 2025-06-30StandaloneEquity to asset ratio (5-year summary)
Shares issued78,940,200at 2026-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued68,453,800at 2025-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued68,053,800at 2025-06-30StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 16
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2026-01-01 → 2026-06-30−¥269m
Drug Discovery And Developmentreportable segmentsegment profit2026-01-01 → 2026-06-30−¥369m
Drug Discovery Supportreportable segmentrevenue2026-01-01 → 2026-06-30¥274m
Drug Discovery Supportreportable segmentrevenue external2026-01-01 → 2026-06-30¥274m
Drug Discovery Supportreportable segmentsegment profit2026-01-01 → 2026-06-30¥159m
Total Of Reportable Segments And Otherssegment totalrevenue2026-01-01 → 2026-06-30¥274m
Total Of Reportable Segments And Otherssegment totalrevenue external2026-01-01 → 2026-06-30¥274m
Total Of Reportable Segments And Otherssegment totalsegment profit2026-01-01 → 2026-06-30−¥210m
Reconciling Itemsreconcilingsegment profit2025-01-01 → 2025-06-30−¥280m
Drug Discovery And Developmentreportable segmentsegment profit2025-01-01 → 2025-06-30−¥396m
Drug Discovery Supportreportable segmentrevenue2025-01-01 → 2025-06-30¥252m
Drug Discovery Supportreportable segmentrevenue external2025-01-01 → 2025-06-30¥252m
Drug Discovery Supportreportable segmentsegment profit2025-01-01 → 2025-06-30¥139m
Total Of Reportable Segments And Otherssegment totalrevenue2025-01-01 → 2025-06-30¥252m
Total Of Reportable Segments And Otherssegment totalrevenue external2025-01-01 → 2025-06-30¥252m
Total Of Reportable Segments And Otherssegment totalsegment profit2025-01-01 → 2025-06-30−¥257m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 430
ItemContextValueUnit
Independent auditors report non consolidated (text)FilingDateInstantText · Plus
Audit firm1 non consolidatedFilingDateInstant
Original text (Japanese)太 陽 有 限 責 任 監 査 法 人
Cpa1 audit firm1 non consolidatedFilingDateInstant
Original text (Japanese)田 村  知 弘
Cpa2 audit firm1 non consolidatedFilingDateInstant
Original text (Japanese)櫻 井  純 一
Number of submissionFilingDateInstant1
Net sales (5-year summary)Prior1InterimDuration_NonConsolidatedMember251796000JPY
Net sales (5-year summary)InterimDuration_NonConsolidatedMember273659000JPY
Net sales (5-year summary)Prior1YearDuration_NonConsolidatedMember593290000JPY
Ordinary income loss (5-year summary)Prior1InterimDuration_NonConsolidatedMember-539020000JPY
Ordinary income loss (5-year summary)InterimDuration_NonConsolidatedMember-481622000JPY
Ordinary income loss (5-year summary)Prior1YearDuration_NonConsolidatedMember-989127000JPY
Net income loss (5-year summary)Prior1InterimDuration_NonConsolidatedMember-540290000JPY
Net income loss (5-year summary)InterimDuration_NonConsolidatedMember-483242000JPY
Net income loss (5-year summary)Prior1YearDuration_NonConsolidatedMember-982779000JPY
Equity in earnings losses of affiliates if equity method is applied (5-year summary)Prior1InterimDuration_NonConsolidatedMember-JPY
Equity in earnings losses of affiliates if equity method is applied (5-year summary)InterimDuration_NonConsolidatedMember-JPY
Equity in earnings losses of affiliates if equity method is applied (5-year summary)Prior1YearDuration_NonConsolidatedMember-JPY
Capital stock (5-year summary)Prior1InterimInstant_NonConsolidatedMember1065558000JPY
Capital stock (5-year summary)InterimInstant_NonConsolidatedMember1554710000JPY
Capital stock (5-year summary)Prior1YearInstant_NonConsolidatedMember1085523000JPY
Total number of issued shares (5-year summary)Prior1InterimInstant_NonConsolidatedMember68053800
Total number of issued shares (5-year summary)InterimInstant_NonConsolidatedMember78940200
Total number of issued shares (5-year summary)Prior1YearInstant_NonConsolidatedMember68453800
Net assets (5-year summary)Prior1InterimInstant_NonConsolidatedMember1519330000JPY
Net assets (5-year summary)InterimInstant_NonConsolidatedMember1565861000JPY
Net assets (5-year summary)Prior1YearInstant_NonConsolidatedMember1122064000JPY
Total assets (5-year summary)Prior1InterimInstant_NonConsolidatedMember1962725000JPY
Total assets (5-year summary)InterimInstant_NonConsolidatedMember1907125000JPY
Total assets (5-year summary)Prior1YearInstant_NonConsolidatedMember1727504000JPY
Basic earnings loss per share (5-year summary)Prior1InterimDuration_NonConsolidatedMember-7.97
Basic earnings loss per share (5-year summary)InterimDuration_NonConsolidatedMember-6.62
Basic earnings loss per share (5-year summary)Prior1YearDuration_NonConsolidatedMember-14.47
Diluted earnings per share (5-year summary)Prior1InterimDuration_NonConsolidatedMember-
Diluted earnings per share (5-year summary)InterimDuration_NonConsolidatedMember-
Diluted earnings per share (5-year summary)Prior1YearDuration_NonConsolidatedMember-
Dividend paid per share (5-year summary)Prior1InterimDuration_NonConsolidatedMember-
Dividend paid per share (5-year summary)InterimDuration_NonConsolidatedMember-
Dividend paid per share (5-year summary)Prior1YearDuration_NonConsolidatedMember-
Equity to asset ratio (5-year summary)Prior1InterimInstant_NonConsolidatedMember0.769
Equity to asset ratio (5-year summary)InterimInstant_NonConsolidatedMember0.819
Equity to asset ratio (5-year summary)Prior1YearInstant_NonConsolidatedMember0.641
Net cash provided by used in operating activities (5-year summary)Prior1InterimDuration_NonConsolidatedMember-673006000JPY
Net cash provided by used in operating activities (5-year summary)InterimDuration_NonConsolidatedMember-538823000JPY
Net cash provided by used in operating activities (5-year summary)Prior1YearDuration_NonConsolidatedMember-935988000JPY
Net cash provided by used in investing activities (5-year summary)Prior1InterimDuration_NonConsolidatedMember-JPY
Net cash provided by used in investing activities (5-year summary)InterimDuration_NonConsolidatedMember-3733000JPY
Net cash provided by used in investing activities (5-year summary)Prior1YearDuration_NonConsolidatedMember-55463000JPY
Net cash provided by used in financing activities (5-year summary)Prior1InterimDuration_NonConsolidatedMember84678000JPY
Net cash provided by used in financing activities (5-year summary)InterimDuration_NonConsolidatedMember709553000JPY
Net cash provided by used in financing activities (5-year summary)Prior1YearDuration_NonConsolidatedMember133198000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identitynon_consolidated 2025-12-31pass
balance sheet identitynon_consolidated 2026-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2025-12-31pass
statement vs summary · net assetsnon_consolidated 2026-06-30pass
statement vs summary · operating cash flownon_consolidated 2025-01-01/2025-06-30pass
statement vs summary · operating cash flownon_consolidated 2026-01-01/2026-06-30pass
statement vs summary · revenuenon_consolidated 2025-01-01/2025-06-30pass
statement vs summary · revenuenon_consolidated 2026-01-01/2026-06-30pass
statement vs summary · total assetsnon_consolidated 2025-12-31pass
statement vs summary · total assetsnon_consolidated 2026-06-30pass